Yipin Hong: Wholly-owned subsidiary's innovative drug APH03867 tablets receive clinical trial registration application acceptance
Yipin Hong's subsidiary, Guangzhou Yipin Hong Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for its clinical trial application for the innovative drug APH03867. This marks a significant step in the drug's development process. Separately, Shanghai Yancheng Trading Co., Ltd. saw changes in its leadership, with Kelly Zong appointed as the legal representative and manager, and Zhejiang Hongyi Holding Group Co., Ltd. as the sole shareholder. AI